Eight studies assessed the relationship between lncRNA expression levels and biochemical recurrence-free survival (BRFS), whereas 2 studies investigated the relationship between the lncRNA PCAT14 and overall survival (OS), metastasis-free survival (MFS), and prostate cancer-specific survival (PCSS). This evidence concerns the gene PCAT14 and prostate carcinoma.